Curated News
By: NewsRamp Editorial Staff
March 10, 2025
BioCorRx Inc. Acquires FDA-Approved Opioid Withdrawal Medication LUCEMYRA from USWM LLC
TLDR
- BioCorRx Inc. acquires LUCEMYRA, the first non-opioid medication for opioid withdrawal, securing a competitive advantage in addiction treatment market.
- LUCEMYRA, an FDA-approved non-opioid medication, reduces norepinephrine release to suppress neurochemical surge causing opioid withdrawal symptoms in adults.
- BioCorRx's acquisition of LUCEMYRA enhances opioid withdrawal treatment, providing critical relief for patients, and reinforces commitment to combatting the opioid crisis.
- LUCEMYRA, the first non-opioid medication for opioid withdrawal, offers innovative solution, expanding treatment options for patients in addiction recovery.
Impact - Why it Matters
This news matters as it represents a significant step in combating the opioid crisis by providing a non-opioid solution for opioid withdrawal symptoms. The acquisition of LUCEMYRA by BioCorRx Inc. highlights a commitment to expanding addiction treatment offerings and improving access to critical solutions for patients in need.
Summary
BioCorRx Inc. and USWM LLC announced an agreement for BioCorRx Pharmaceuticals Inc. to acquire LUCEMYRA, an FDA-approved medication for opioid withdrawal. LUCEMYRA is the first non-opioid medication approved by the FDA for this purpose, offering relief during detoxification. Under the terms, USWM, LLC will retain royalties and shares of BioCorRx Inc., positioning LUCEMYRA as a key asset in BioCorRx Pharmaceutical Inc.'s product line.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, BioCorRx Inc. Acquires FDA-Approved Opioid Withdrawal Medication LUCEMYRA from USWM LLC
